Status:
RECRUITING
HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma
Lead Sponsor:
Centro Hospitalar de Lisboa Central
Collaborating Sponsors:
Ophiomics - Precision Medicine
Conditions:
Hepatocellular Carcinoma, Scirrhous
Recurrence Tumor
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in cirrhosis. Due to organs shortage, the proper selection of patients is imperative. Prevailing clinical morphologi...
Detailed Description
Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in cirrhosis. Due to organs shortage, the proper selection of patients is imperative. Prevailing clinical morphologi...
Eligibility Criteria
Inclusion
- Hepatocellular carcinoma associated with cirrhosis
- Ages between 18 and 70 years
- Total tumour volume below 500 cm3
- Total number of tumour lesions below 10
- Maximum individual tumour diameter below 10 cm
Exclusion
- eligible under the "Milan Criteria"
Key Trial Info
Start Date :
March 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04499833
Start Date
March 25 2021
End Date
December 31 2029
Last Update
June 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Hepato-bilio-pancreático e de Transplantação do Hospital Curry Cabral
Lisbon, Portugal, 1069-166